(Q45423126)

14 December 2017

Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help (English)

1 reference

14 December 2017

0 references

Andrew James McMichael

series ordinal

2

object named as

Andrew J McMichael

1 reference

14 December 2017

Marie J Estcourt

1

1 reference

PubMed ID

16245361

14 December 2017

Tomás Hanke

series ordinal

3

1 reference

PubMed ID

16245361

14 December 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

European Journal of Immunology

14 December 2017

1 reference

14 December 2017

35

1 reference

14 December 2017

12

1 reference

14 December 2017

3460-3467

1 reference

Early programming of T cell populations responding to bacterial infection

14 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

Listeria monocytogenes infection overcomes the requirement for CD40 ligand in exogenous antigen presentation to CD8(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4+ T-cell help in CD8+ T-cell responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Programmed contraction of CD8(+) T cells after infection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Dynamic programming of CD8+ T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Helper activity is required for the in vivo generation of cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

In vivo induction of antigen-specific transplantation tolerance to Qa1a by exposure to alloantigen in the absence of T-cell help

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Estimating the precursor frequency of naive antigen-specific CD8 T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Studies on poxvirus infections in irradiated animals

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

In vivo compartmentalization of functionally distinct, rapidly responsive antigen-specific T-cell populations in DNA-immunized or Salmonella enterica serovar Typhimurium-infected mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

CD8+ T cells responding to influenza infection reach and persist at higher numbers than CD4+ T cells independently of precursor frequency

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Phenotypic analysis of antigen-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

CD4 monoclonal antibody pairs for immunosuppression and tolerance induction

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200526284

7 January 2021

Identifiers

DOI

10.1002/EJI.200526284

1 reference

14 December 2017

1 reference

PubMed ID

16245361